Bharat Biotech joins global efforts in developing coronavirus vaccine

CoroFlu will build on the backbone of vaccine firm FluGen's flu vaccine candidate, a self-limiting version of the influenza virus that induces an immune response against the flu.

coronavirus, test
Premium

A representative image of medical professional testing for coronavirus.

Dasarath Reddy Hyderabad
Hyderabad-based vaccine maker Bharat Biotech said today that it was a part of an international collaboration of virologists and vaccine companies that has begun working on the development and testing CoroFlu, of a unique intranasal vaccine against Covid-19.

CoroFlu will build on the backbone of vaccine company FluGen's flu vaccine candidate known as M2SR, which  is a self-limiting version of the influenza virus that induces an immune response against the flu. FluGen's lab will insert gene sequences from SARS-CoV-2, the coronavirus that causes Covid-10, into M2SR sot that the new vaccine will also induce immunity against the pathogen.

Sharing the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Apr 03 2020 | 3:02 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com